FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Bid/Ask 10:14:46 23/05/2024 pm IST | After market 11:39:04 pm | |||
| 6.41 EUR | -2.44% |
|
6.455 | +0.70% |
| Current month | -15.12% | ||
| 1 month | +12.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 6.41 | -2.44% |
| 22/24/22 | 6.57 | -11.10% |
| 21/24/21 | 7.39 | +19.58% |
| 20/24/20 | 6.18 | -2.06% |
| 17/24/17 | 6.31 | -6.52% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 10:14 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME9MAF |
| ISIN | DE000ME9MAF4 |
| Date issued | 05/03/2024 |
| Strike | 415.1 kr |
| Maturity | Unlimited |
| Parity | 3.89 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.09 € |
|---|---|
| Lowest since issue | 5.82 € |
| Spread | 0.19 € |
| Spread % | 2.88% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
613.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.05%
- Stock Market
- Certificates
- Certificat
